Clinical trial
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)
ClinicalTrials.gov ID: NCT01908426
Sponsor: Exelixis
Information provided by: Exelixis (Responsible Party)
Last Update Posted: 2021-05-06
Brief Summary:
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
Official Title:
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Intervention / Treatment:
- Drug: Cabozantinib tablets
- Drug: Placebo tablets
| Category | Value |
|---|---|
| Study Start (Actual) | 2013-09-26 |
| Primary Completion (Actual) | 2017-10-16 |
| Study Completion (Actual) | 2021-01-12 |
| Enrollment (Actual) | 707 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
XL184-309
|